|
| During public health emergencies (PHEs) involving chemical, biological, radiological, or nuclear threats or emerging infectious diseases, medical countermeasures (MCMs) (e.g., drugs, vaccines, devices) may need to be dispensed or administered to affected populations to help mitigate the human health impact of the threat. The optimal MCMs determined for use during an emergency might be U.S. Food and Drug Administration (FDA) approved but used in unapproved ways (e.g., in a new age group or against a new agent) FDA approved using animal models because human efficacy testing is not ethical or feasible; or not yet FDA approved for any indication. |
|
| |
| Binding: Softcover |
| Specs: 105 pages | .47 Lbs |
| ISBN: 0309466423 |
| ISBN-13: 9780309466424 |
| Edition: 1 |
| Publisher: National Academies Press | Publish Date 12/17 | Copyright 2017 |
| |
|
| |
|
|